Streetbeat News

OKUR

OnKure Therapeutics, Inc.

Industry

Biotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

HC Wainwright & Co. has initiated coverage on OnKure Therapeutics with a Buy rating and set a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 1:42 pm

Okur Cormorant Asset Management has reported a 14.98% passive stake in Onkure Therapeutics, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 8:38 pm

OnKure Therapeutics Inc (NASDAQ:OKUR) has completed a merger with Reneo Pharmaceuticals and initiated trading. Oppenheimer has given OnKure an Outperform rating with a $35 price target, highlighting its innovative breast cancer treatment, OKI-219. The company has secured $65 million in private placement, ensuring a cash runway through Q4-2026. OKI-219 is noted for its selectivity in targeting PI3Kα mutations, offering a promising alternative to Novartis AG's (NYSE:NVS) alpelisib, which faces toxicity concerns.

Portfolio Pulse from Vandana Singh

October 10, 2024 | 6:43 pm

Top Wall Street analysts initiated coverage on several companies, including Align Technology, SiteOne Landscape Supply, OnKure Therapeutics, IperionX Limited, and Builders FirstSource. Notably, Builders FirstSource received a Buy rating from Goldman Sachs with a price target of $225.

Portfolio Pulse from Avi Kapoor

October 10, 2024 | 1:00 pm

Oppenheimer has initiated coverage on OnKure Therapeutics with an Outperform rating and set a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:07 pm

The trading halt status was updated at 8:55:00 AM ET, indicating a quotation resumption. This update is crucial for investors tracking the affected securities.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 12:55 pm

Trading for a company has been halted at 7:20:34 a.m. ET due to pending news. This indicates that significant information is expected to be released, which could impact the stock price.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:20 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.